Dr. Shore Comments on the Approval of Radium-223

Neal D. Shore, MD
Published: Thursday, Sep 19, 2013

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the approval of radium-223 for patients with bone metastases from prostate cancer.

Shore believes that the FDA approved radium-223 so quickly because of the robust data regarding efficacy and toleration. Radium-223 demonstrated an improvement in survival and delay in skeletal complications for patients with bone metastases and was well-tolerated, with no significant myelosuppression. As the radioisotope is cleared through the intestinal tract and excreted fecally, mild events of diarrhea were observed, Shore says.

Radium-223 is given intravenously over a period of about 45-60 seconds and is administered once every 4 weeks for 6 administrations. Additionally, Shore says, the agent must be administered by someone with the appropriate licensure.
 
SELECTED
LANGUAGE
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the approval of radium-223 for patients with bone metastases from prostate cancer.

Shore believes that the FDA approved radium-223 so quickly because of the robust data regarding efficacy and toleration. Radium-223 demonstrated an improvement in survival and delay in skeletal complications for patients with bone metastases and was well-tolerated, with no significant myelosuppression. As the radioisotope is cleared through the intestinal tract and excreted fecally, mild events of diarrhea were observed, Shore says.

Radium-223 is given intravenously over a period of about 45-60 seconds and is administered once every 4 weeks for 6 administrations. Additionally, Shore says, the agent must be administered by someone with the appropriate licensure.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x